Equities research analysts expect Zogenix, Inc. (NASDAQ:ZGNX) to announce earnings per share (EPS) of ($1.00) for the current quarter, Zacks reports. Zero analysts have provided estimates for Zogenix’s earnings, with estimates ranging from ($1.09) to ($0.92). Zogenix reported earnings of ($1.14) per share during the same quarter last year, which suggests a positive year-over-year growth rate of 12.3%. The business is scheduled to announce its next earnings results on Tuesday, March 5th.
According to Zacks, analysts expect that Zogenix will report full year earnings of ($3.84) per share for the current financial year, with EPS estimates ranging from ($4.22) to ($3.70). For the next financial year, analysts forecast that the business will report earnings of ($3.97) per share, with EPS estimates ranging from ($4.60) to ($3.02). Zacks’ EPS averages are a mean average based on a survey of analysts that cover Zogenix.
Zogenix (NASDAQ:ZGNX) last announced its quarterly earnings data on Thursday, November 8th. The company reported ($1.08) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.88) by ($0.20). During the same period in the prior year, the business earned ($1.68) EPS.
In related news, CEO Stephen J. Farr sold 90,313 shares of Zogenix stock in a transaction dated Thursday, January 10th. The shares were sold at an average price of $45.00, for a total value of $4,064,085.00. Following the sale, the chief executive officer now directly owns 52,259 shares in the company, valued at approximately $2,351,655. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Erle T. Mast sold 1,468 shares of Zogenix stock in a transaction dated Monday, November 26th. The shares were sold at an average price of $42.08, for a total transaction of $61,773.44. Following the completion of the sale, the director now owns 3,027 shares in the company, valued at $127,376.16. The disclosure for this sale can be found here. Over the last quarter, insiders sold 111,781 shares of company stock worth $4,952,858. 4.60% of the stock is currently owned by insiders.
A number of large investors have recently modified their holdings of ZGNX. BlueMountain Capital Management LLC bought a new stake in Zogenix in the 2nd quarter valued at about $104,000. SG Americas Securities LLC bought a new stake in Zogenix in the 3rd quarter valued at about $109,000. FNY Investment Advisers LLC lifted its position in Zogenix by 3,900.0% in the 3rd quarter. FNY Investment Advisers LLC now owns 3,000 shares of the company’s stock valued at $148,000 after purchasing an additional 2,925 shares during the last quarter. Prudential Financial Inc. bought a new stake in Zogenix in the 3rd quarter valued at about $219,000. Finally, Public Employees Retirement Association of Colorado bought a new stake in Zogenix in the 3rd quarter valued at about $226,000.
Shares of ZGNX stock opened at $44.46 on Friday. The firm has a market cap of $1.86 billion, a price-to-earnings ratio of -11.06 and a beta of 1.79. Zogenix has a 1-year low of $33.43 and a 1-year high of $62.75.
Zogenix Company Profile
Zogenix, Inc, a pharmaceutical company, develops and commercializes therapies for the treatment of central nervous system disorders in the United States. Its lead product candidate is the ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome.
Featured Article: Quick Ratio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.